Pfizer: positive data for Covid vaccine for children
(CercleFinance.com) - Pfizer and BioNTech have announced positive safety, immunogenicity and efficacy data from a Phase 2/3 trial evaluating a third 3 μg dose of their Covid-19 vaccine in children aged six months to less than five years.
After a third dose in this age group, the vaccine was shown to elicit a strong immune response, with a favourable safety profile similar to placebo, they said, displaying an observed vaccine efficacy of 80.3%.
This analysis was based on 10 symptomatic cases identified seven days after the third dose and a formal analysis will be conducted with at least 21 cumulative cases. Final efficacy data will be reported very soon.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
After a third dose in this age group, the vaccine was shown to elicit a strong immune response, with a favourable safety profile similar to placebo, they said, displaying an observed vaccine efficacy of 80.3%.
This analysis was based on 10 symptomatic cases identified seven days after the third dose and a formal analysis will be conducted with at least 21 cumulative cases. Final efficacy data will be reported very soon.
Copyright (c) 2022 CercleFinance.com. All rights reserved.